LGM
AVTX icon

Logos Global Management’s Avalo Therapeutics AVTX Stock Holding History

Logos Global Management’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.48M Buy
+300,000
New +$4.69M 0.22% 57
2024
Q4 		– Sell
-539,079
Closed -$5.12M – 50
2024
Q3 		$5.12M Hold
539,079
– – 0.55% 42
2024
Q2 		$6.72M Buy
+539,079
New +$6.99M 0.54% 43

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Logos Global Management's AVTX Position: Q1 2026 in Review

Logos Global Management opened a new position in Avalo Therapeutics (AVTX) in Q1 2026: 300,000 shares worth $4.48M. The stake represents 0.22% of the portfolio and ranks #57 among its holdings. This is a return to the name: Logos Global Management previously reported a position in AVTX as recently as Q3 2024.

Logos Global Management first reported a position in AVTX in Q2 2024 and has held it in 3 quarters since. The position peaked at $6.72M in Q2 2024. 97 funds tracked by Wall St. Rank hold AVTX as of Q1 2026.

  • Logos Global Management held 300,000 shares of Avalo Therapeutics worth $4.48M as of Q1 2026.
  • Avalo Therapeutics was a new Logos Global Management position in Q1 2026.
  • Avalo Therapeutics made up 0.22% of Logos Global Management's portfolio in Q1 2026, its #57 holding.
  • Logos Global Management first reported a position in Avalo Therapeutics in Q2 2024 and has held it in 3 quarters since.
  • Logos Global Management's Avalo Therapeutics position peaked at $6.72M in Q2 2024.
  • 97 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2026.

Based on Logos Global Management's 13F filing for Q1 2026, filed 15 May 2026.